Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Georgia Bard's Corner -- Ignore unavailable to you. Want to Upgrade?

To: Loren S. who wrote (8337)	12/17/1999 9:59:00 AM
From: Loren S.	Read Replies (1) \| Respond to of 9440

SIMU is a real sleeper of a stock with a very low float that is going to go much higher in time: Simulations Plus Receives Global Order From Roche for All Three Pharmaceutical Software Products LANCASTER, Calif./Nutley, N.J.--(BUSINESS WIRE)--Dec. 16, 1999-- GastroPlus(tm), GastroPlus(tm) Optimization Module, and QMPRPlus(tm) To Be Shipped to All of Roche's Pharmaceutical Research Centers Worldwide Simulations Plus Inc. (OTCBB:SIMU) (www.simulations-plus.com), a premier developer of drug discovery and development simulation software for the pharmaceutical industry, today announced that it has received a global order from Hoffmann-La Roche Inc. (Roche) for all three of its current pharmaceutical software products. Licenses for each of these three software products, which include GastroPlus(tm), GastroPlus(tm) Optimization Module, and QMPRPlus(tm), will be issued to each of Roche's global research centers. Terms of this purchase were not disclosed. "Our global organization continues to search for predictive tools that will assist us in identifying quality clinical candidates," stated Dr. Louis Renzetti, research director, Discovery Pharmacology at Roche. "We are very impressed with the use of this technology so far, which represents a ready-made solution, and believe it will enable us to select more effective clinical candidates and then also chart their pharmacokinetic profiles once they are in the clinic." Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "We are extremely pleased that Roche has selected our software to support its research in the area of oral absorption. This order, coming after a year of use of GastroPlus(tm) at the Nutley research center, confirms the value of our software in support of reducing the time and costs to bring new drugs to market. We look forward to continuing the excellent relationship that has developed between Roche and Simulations Plus." Simulations Plus is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical companies worldwide. The Company has two other businesses, Words+ Inc. and FutureLab(tm), which are based on its proprietary software technologies and which provide support for the emerging pharmaceutical enterprise. Simulations Plus has headquarters in Southern California and trades on the OTCBB under the symbol "SIMU." Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics, vitamins, and fragrances and flavors. Roche discovers, develops, manufactures and markets numerous important prescription drugs that enhance people's health, well-being and quality of life. Among the company's areas of therapeutic interest are: virology, including HIV/AIDS and hepatitis C; infectious diseases, including influenza; cardiology; neurology; oncology; transplantation; dermatology; and metabolic diseases including obesity and diabetes. For more information on the Roche pharmaceuticals business in the United States, visit the company's Web site at: rocheusa.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: continuing demand for the Company's products; competition, continuing customer acceptance of the Company's products and acceptance of the Company's new products. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports as filed with the Securities and Exchange Commission. CONTACT: Simulations Plus Inc., Lancaster Ron Creeley, 661/723-7723 or Banchik & Associates, Solvang, Calif. Doris Banchik, 805/688-2340 or Hoffmann-La Roche Inc., Nutley Darien E. Wilson, 973/562-2232 KEYWORD: CALIFORNIA NEW JERSEY

To: Loren S. who wrote (8337)	12/22/1999 10:29:00 AM
From: Loren S.	Respond to of 9440

CRA and GENE have been on fire. Both are genomics related stocks. LDNA is an unknown OTC in the same field. Only 3 million outstanding, trading under $2.00. The company has contracts with huge players in the health care industry and they are profitable. (PR Wires) PRW: Lark Announces Quarterly Earnings; Record Revenues in T PRW: Lark Announces Quarterly Earnings; Record Revenues in Third Quarter 1999 HOUSTON--(BUSINESS WIRE)--Nov. 15, 1999--Lark Technologies Inc. (OTCBB:LDNA) announced record revenues for the quarter ended September 30, 1999. Revenues achieved the highest level for any quarter at Lark. Revenues increased 117% to $1,468,824 in the third quarter of 1999 from revenues of $678,333 in the third quarter of 1998. Net income for the third quarter of 1999 was $156,756 or $0.05 per share, as compared to a loss of $410,451 or $0.12 per share for the third quarter of 1998. For the nine months ending September 30, 1999, revenue increased 22% to $3,712,762 compared to $3,054,924 during the same period in 1998. Net income for the first nine months of 1999 was a loss of $81,831 or $0.02 per share compared to a loss of $199,816 or $0.06 per share for the first nine months of 1998. Vince Kazmer, Lark's president, commented "We are very pleased with the results of our efforts during the third quarter. In prior years the third quarter was usually the weakest quarter of the year due to seasonality factors. To achieve record revenues during the third quarter speaks highly of both our sales/marketing team and operations staff. The revenues were attributable to good demand for Lark's services in both the US and UK. Lark's revenue included strong performance for sequencing services and new product lines such as Quantitative PCR services. Additionally, our revenue mix was not dependent on a single large customer but consisted of a wide range of customers." Mr. Kazmer continued, "We have experienced a steady rise in our average monthly bookings for each quarter of this year. The average monthly bookings for the first, second and third quarters of 1999 were approximately $285,000, $420,000 and $493,900 respectively. These results support the effectiveness of Lark's genomic services business model. Demand for Lark's genomic services is driven by the discovery of new genes and related novel drug development targets. These services now support the drug development pathway from research through clinical trials. Demand for Lark's capabilities in the agricultural business sector is also growing due to increased pressures for development and testing of genetically modified crops." Separately, Mr. Steve Banks, chairman of Lark's Board of Directors, noted that the Board accepted Mr. Vince Kazmer's resignation as president of Lark effective November 30, 1999. Mr. Kazmer has decided to pursue other corporate ventures, and Lark's Board is appreciative of all his contributions to the Company and wish him well in the future. Mr. Banks expects the announcement of a new acting president very shortly. Mr. Banks also stated the company would continue its activities to raise additional funds in order to implement a more aggressive growth strategy. Lark Technologies Inc., based in Houston, Texas, is a leading molecular biology contract research organization (CRO) serving the rapidly growing genomics industry. The company was founded in 1989 by BCM Technologies Inc., the wholly-owned venture, technology transfer subsidiary of Baylor College of Medicine. Lark's stock is quoted on the OTC Bulletin Board under the symbol "LDNA". Company information is located at its website (http://www.lark.com). Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These forward-looking statements speak only as of the date hereof. Lark disclaims any intent or obligation to update these forward-looking statements.